Sickle cell experts say a cure without care jeopardizes the freedom promised by new gene therapies
Two new, cutting-edge cures for sickle cell disease, a debilitating genetic blood disorder, have been approved on Friday. The sickle cell community is cautiously hopeful as questions around access and comprehensive care loom large. The U.S. Food and Drug Administration approved Exa-cel, also known by its commercial name Casgevy. It’s a gene-editing therapy that uses…
